Showing 2081-2090 of 5789 results for "".
- US FDA Grants Breakthrough Device Designation to Marpe's Dermatology Screening Systemhttps://practicaldermatology.com/news/us-fda-grants-breakthrough-device-designation-to-marpes-dermatology-screening-system/2461900/The US Food and Drug Administration (FDA) has granted Breakthrough Device designation to Marpe Technologies full-body Dermatology Screening System. The Marpe System is designed to acquire and analyze total body images to support the identification of malignant and pre-malignant lesions,
- Lupus Foundation of America Awards Five Summer Fellowship Grantshttps://practicaldermatology.com/news/lupus-foundation-of-america-awards-five-summer-fellowship-grants/2461899/The Lupus Foundation of America announced five recipients of the
- Sirnaomics Appoints Dr. Francois Lebel as Senior Vice President for Preclinical and Clinical Developmenthttps://practicaldermatology.com/news/sirnaomics-appoints-dr-francois-lebel-as-senior-vice-president-for-preclinical-and-clinical-development/2461896/Dr. Francois Lebel, M.D is the new Senior Vice President for preclinical and clinical development at Sirnaomics Ltd. "With multiple drug candidates moving into clinical studies, including two clinical trials advancing to late-stage development, Sirnaomics is embarkin
- Research Closes in on the Genetic Factors Underlying HS Riskhttps://practicaldermatology.com/news/research-closes-in-on-the-genetic-factors-underlying-hs-risk/2461893/Researchers have identified genetic locations for increased risk of hidradenitis suppurativa (HS). “This discovery is highly relevant because these changes may effect nearby genes in a way that leads to improper development of hair follicles and predispose them to the rupture,&rdq
- FDA Approves Verrica Pharmaceuticals’ YCANTH for Molluscum Contagiosumhttps://practicaldermatology.com/news/fda-approves-verrica-pharmaceuticals-ycanth-for-molluscum-contagiosum/2461882/The U.S. Food and Drug Administration (FDA) has given its nod to Verrica Pharmaceuticals Inc.’s YCANTH (cantharidin) topical solution for the treatment of molluscum contagiosum in adult and pediatric patients aged two and older. "It's the only topical FDA-approved therapy
- First AD Patient Dosed in Lynk Pharmaceuticals' Phase Ib Clinical Study of Topical JAK Inhibitorhttps://practicaldermatology.com/news/first-ad-patient-dosed-in-lynk-pharmaceuticals-phase-ib-clinical-study-of-topical-jak-inhibitor/2461881/The first atopic dermatitis (AD) patient has been dosed in a Phase Ib clinical trial of LNK01004, Lynk Pharmaceuticals Co., Ltd. The trial was designed to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of LNK01004 ointment in Chinese patient
- MRA Announces 2023 Dermatology Fellowship Award Recipientshttps://practicaldermatology.com/news/mra-announces-2023-dermatology-fellowship-award-recipients/2461878/The Melanoma Research Alliance (MRA) has announced its 2023 Dermatology Fellowship Award recipients. The awardees will each receive a $50,000 grant to support an independent research project focused on advancing melanoma prevention or detection. Along with critical finan
- FDA Clears Xstrahl’s Radiant Aura for NMSCshttps://practicaldermatology.com/news/fda-clears-radiant-aura-receives-us-food-and-drug-administration-fda-510k-clearance/2461871/The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to Xstrahl’s Radiant Aura, an office-based radiation therapy for non-melanoma skin cancer (NMSC). “We developed Radiant Aura to deliver both electronic brachytherapy and superficial radiation therapy in
- Warts and All: Novan Files Chapter 11, Sells Assetshttps://practicaldermatology.com/news/warts-and-all-novan-files-chapter-11-sells-assets/2461870/Novan is selling all of its assets, including Berdazimer Gel, 10.3% (SB206), and has filed for Chapter 11 Protection. The Company entered into a stalking horse asset purchase agreement (APA) with Ligand Pharmaceuticals, Inc. prior to filing voluntary petitions for relief unde
- Arcutis’ ZORYVE Now in Preferred Position on National Formularies for CVS Caremarkhttps://practicaldermatology.com/news/arcutis-zoryve-now-in-preferred-position-on-national-formularies-for-cvs-caremark/2461868/Arcutis Biotherapeutics, Inc.’s ZORYVE (roflumilast) cream 0.3% for the treatment of plaque psoriasis, including intertriginous psoriasis in adults and adolescents, is now covered as a preferred tier product on national formularies for CVS Caremar